Science keeps winning! Scientists recently transplanted a pig’s kidney into a human being without immediate rejection by the immune system.
A step in the right direction, the achievement could help ease the shortage of human organs for transplant by using animal organs.
Performed at the NYU Langone Health in New York City, the procedure used the kidney of a pig whose genes had been modified to get rid of a particular molecule which causes human immune systems to reject animal organs.
According to Reuters, the recipient of the pig kidney is a comatose patient who was experiencing kidney dysfunction. The subject’s family consented to the pig kidney transplantation before she was set to be taken off life support.
How was the procedure done?
In the pilot phase of the transplant, the pig kidney was attached to her blood vessels but kept outside the body. This gave researchers access to the kidney for three days in case things were to go awry.
The kidney function after the transplant appears to be normal so far. Turns out the kidney is also making as much urine as expected from a kidney. In fact, Dr. Robert Montgomery, the lead researcher of the study told Reuters that it’s working akin to a human kidney.
The most telling sign of the pig kidney working? The recipient’s kidney function has become normal again. Earlier, the subject’s creatinine levels were abnormal and now they appear stable.
Kidney shortage in India
Researchers across the globe have been working for decades to transplant animal kidneys into humans. Unfortunately, the immediate rejection has remained extremely high among recipients. With this new pig kidney transplant, things may be headed for a shake-up.
According to Narayana Health, almost 200,000 patients in India are awaiting organ donation with only 15,000 available donors. This gap could be filled with animal transplants modelled around this one.
Reference:
https://www.indiatimes.com/technology/science-and-future/pig-kidney-transplant-in-human-552148.html
Global shipping costs have climbed to $4,000–$4,500 in October from $2,000–$2,500 in February 2026. Freight rates, which had eased through much of 2025 and early 2026 as the demand-supply balance improved, have rebounded sharply in recent months. The increase has brought shipping costs back into focus for businesses dependent on international cargo movement.
The U.S. Food and Drug Administration (FDA) has finalized guidance outlining how manufacturers should report post-approval manufacturing changes for biosimilar and interchangeable biosimilar products. The guidance provides greater regulatory clarity on changes involving production processes, manufacturing sites, analytical methods, raw materials, and process controls. It aims to ensure product quality while reducing unnecessary regulatory burden.
A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.
The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.
On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.
Following a series of typhoon disruptions in East China during the month of August, major ports including Shanghai and Ningbo continue to experience congestion and operational recovery challenges. Industry reports indicate that vessel schedules, yard operations, and equipment circulation remain affected as terminals work through accumulated backlogs from successive storm events.
Under REACH Annex XVII Entry 78, the EU has banned the placing on the market of synthetic polymer microparticles (SPMs) unless a specific derogation applies. Derogations exist for essential uses such as:
As a result of the amendment of the CLP Regulation (Regulation (EC) No 1272/2008 on the classification, labelling and packaging of substances and mixtures), new hazard classes have entered into force.
In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.